Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24632392 | 0.86 | TSHR (0.40) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL27413998 | 0.86 | TSHR (0.40) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL19060085 | 0.86 | TSHR (0.40) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL6981519 | 0.86 | TSHR (0.40) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL9911316 | 0.86 | TSHR (0.40) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL10291116 | 0.84 | ALOX15 (0.33) | ALDH1A1CYP3A4TP53 | |
| SCHEMBL10291469 | 0.81 | ALDH1A1 (0.37) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL18666899 | 0.80 | PDK1 (0.37) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL16197748 | 0.78 | PDK1 (0.39) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 | |
| SCHEMBL16197759 | 0.78 | PDK1 (0.39) | PDK1ALDH1A1NLRP3CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| US-7811998-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | UNIVERSITY OF KANSAS (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | US | disclosed |
| US-7622451-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2009-11-24 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | SSB, IAPP, NLN | PDK1 4057/4885ALDH1A1 4309/4885NLRP3 372/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | PDK1 1890/4885ALDH1A1 3407/4885NLRP3 321/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | PDK1 814/4885ALDH1A1 3066/4885NLRP3 2505/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | PDK1 187/4885ALDH1A1 4382/4885NLRP3 2958/4885 |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | HSP90B1, HSP90AB2P, HSP90AB1 | PDK1 1691/4885ALDH1A1 2718/4885NLRP3 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.